NCT06790420 2025-05-31
RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study
Pfizer
Completed
Clinical Trials
18 trialsNCT02536664 2023-04-18
Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Hoffmann-La Roche
Completed
NCT03289182 2021-01-11
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Completed
NCT03582098 2019-04-12
RETRO-idel
Gilead Sciences
Completed
NCT01178086 2018-10-05
A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Hoffmann-La Roche
Completed
NCT01609023 2018-06-26
CaLLypso
Hoffmann-La Roche
Completed
NCT02654379 2018-04-09
Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe
Hoffmann-La Roche
Completed
NCT01684865 2017-12-29
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Completed
NCT02472756 2017-08-01
REFLECT 2
Hoffmann-La Roche
Completed
NCT01224093 2016-11-02
An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)
Hoffmann-La Roche
Completed
NCT01072240 2016-11-01
An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Completed
NCT01613027 2016-10-24
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
Hoffmann-La Roche
Completed
NCT01641952 2016-08-17
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
Hoffmann-La Roche
Completed
NCT02110394 2016-07-06
NORMA
Astellas Pharma Inc
Completed
NCT02316613 2016-02-25
Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)
Hoffmann-La Roche
Completed
NCT02072967 2016-02-22
Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Astellas Pharma Inc
Completed
NCT02486952 2016-02-22
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
Hoffmann-La Roche
Completed
NCT02461290 2015-09-30
Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1
Hoffmann-La Roche
Completed